Formulation and Evaluation of a Protein-loaded Solid Dispersions by Non-destructive Methods
- 248 Downloads
The purpose of this investigation was to develop solid dispersion (SD) formulation of cyclosporine (CyA) using polyethylene glycol (PEG-6000) to enhance its dissolution rate followed by nondestructive method for the prediction of both drug and carrier. SD formulations were prepared by varying the ratio of CyA and PEG-6000 by solvent evaporation technique and characterized by dissolution, scanning electron microscopy (SEM), differential scanning calorimetry (DSC), Fourier transform infrared (FTIR), powder X-ray diffraction (PXRD), near infrared (NIR) and near infrared chemical imaging (NIR-CI). Dissolution data revealed enhanced dissolution of CyA when compared with pure CyA. DSC results showed that the crystallinity of PEG-6000 has decreased as indicated by decrease in the enthalpy of fusion and melting peak in the formulations. FTIR data demonstrated no chemical interaction between drug and carrier. The surface morphology of SD formulations was similar to PEG-6000 particle. NIR-CI disclosed homogeneity of SD matrix as indicated by symmetrical histograms with smaller values of skewness. Similar to NIR, a multivariate peak evaluation with principal component analysis and partial least square (PLS) were carried out with PXRD spectral data. PLS models with both techniques showed good correlation coefficient and smaller value of root mean square of errors. The accuracy of model for predicting CyA and PEG-6000 in NIR and PXRD data were 5.22%, 5.35%, 5.27%, and 2.10%, respectively. In summary, chemometric applications of non-destructive method sensors provided a valuable means of characterization and estimation of drug and carrier in the novel formulations.
Key wordscyclosporin NIR PEG-6000 PXRD solid dispersion
The authors would like to thank the Oak Ridge Institute for Science and Education (ORISE) for supporting post doctoral research program. The views presented in this article do not necessarily reflect those of the US Food and Drug Administration.
- 2.Taylor NE, Mark AE, Vallat P, Brunne RM, Testa B, Van Gunteren WF. Solvent dependent conformation and hydrogen bounding capacity of cyclosporin A: evidence from partition coefficient and molecular dynamic simulations. J Med Chem. 1993;36:3753–64.Google Scholar
- 18.Takada K, Oh-hashi M, Furuya Y, Yoshikawa H, Muranishi S. Enteric solid dispersion of cyclosporin A (CyA) having potential to improve availability of CyA in rabbit. Chem Pharm Bull (Tokyo). 1989;37:2542–4.Google Scholar
- 19.FDA/CDER Guidance for industry. PAT-A framework for innovative pharmaceutical development, manufacturing, and quality assurance. September 2004Google Scholar
- 23.Lewis EN, Schoppelrei J, Lee E. Molecular spectroscopy workbench near-infrared chemical imaging and the PAT initiative. Spectrosc. 2004;19:26–36.Google Scholar
- 28.Stephenson GA, Young R. Potential applications of Rietveld analysis in the pharmaceutical industry. Am Pharm Rev. 2001;4:46–51.Google Scholar
- 30.Mateos AG (1992) Quantitative XRD analysis by partial least squares application in a commercial product. In: Barrett JV, SC, Gilfrich, Huang TC, Jenkins R, Mc Carthy GJ, Predecki PK, Ryon R, Smith DK (eds) Advances in X-ray analysis. Plenum Publishing Corporation, New York, 35:117-126Google Scholar
- 33.Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem Instrum. 1965;4:117–212.Google Scholar